
BE Biosol, Gates Foundation Partner on Anaemia Injection
The story in brief
BE Biosol and the Gates Foundation have signed an agreement to develop Ferric Carboxymaltose injection for iron deficiency anaemia. The collaboration will support scale-up and clinical development in target markets, including Africa, using BE Biosol’s manufacturing and R&D capabilities. The initiative aims to improve accessibility of the injection in multiple countries.